Applicants,Chemical_Name,Funding_requested_for,Pharmaceutical,Priority_List,Schedules,Therapeutic_group
"Clinician, Consumer",Mirabegron,"Overactive bladder, 2nd line",Mirabegron,Recommended for decline,,Genito-Urinary System
